Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA

[
Ascletis Announces Positive Topline Results of U.S. Phase Ib Multiple Ascending Dose Study of Small Molecule Oral GLP-1R Agonist ASC30 and Submission of 13-week Phase IIa Study Protocol to FDA
[og_img]
https://www.investing.com/news/press-releases/ascletis-announces-positive-topline-results-of-us-phase-ib-multiple-ascending-dose-study-of-small-molecule-oral-glp1r-agonist-asc30-and-submission-of-13week-phase-iia-study-protocol-to-fda-93CH-3997171


Investing.com